Management of atrial fibrillation after transcatheter aortic valve replacement: Challenges and therapeutic considerations.
Ablation Techniques
/ adverse effects
Anti-Arrhythmia Agents
/ adverse effects
Anticoagulants
/ adverse effects
Atrial Fibrillation
/ diagnosis
Cardiac Catheterization
/ adverse effects
Comorbidity
Humans
Platelet Aggregation Inhibitors
/ adverse effects
Prevalence
Risk Assessment
Risk Factors
Stroke
/ mortality
Transcatheter Aortic Valve Replacement
/ adverse effects
Treatment Outcome
Anticoagulation
Atrial fibrillation
Transcatheter aortic valve replacement
Journal
Trends in cardiovascular medicine
ISSN: 1873-2615
Titre abrégé: Trends Cardiovasc Med
Pays: United States
ID NLM: 9108337
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
02
05
2020
revised:
22
06
2020
accepted:
23
06
2020
pubmed:
1
7
2020
medline:
18
8
2021
entrez:
30
6
2020
Statut:
ppublish
Résumé
Atrial Fibrillation (AF) is very common among patients with severe aortic stenosis. Moreover, new onset AF (NOAF) is a frequent finding after Transcatheter Aortic Valve Replacement (TAVR). There is a significant impact of AF on outcomes in patients undergoing TAVR including mortality, thrombo-embolic and bleeding events. There is lack of clear evidence about the optimal management of AF in TAVR patients. This review aims to summarize the epidemiology, predictors, prognosis, therapeutic considerations and challenges in the management of AF in patients undergoing TAVR.
Identifiants
pubmed: 32599334
pii: S1050-1738(20)30086-4
doi: 10.1016/j.tcm.2020.06.007
pii:
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-367Commentaires et corrections
Type : CommentIn
Informations de copyright
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.